1,818
Views
7
CrossRef citations to date
0
Altmetric
Articles

PSA testing patterns in a large Swedish cohort before the implementation of organized PSA testing

ORCID Icon, , , , , , ORCID Icon & show all
Pages 376-381 | Received 29 Apr 2020, Accepted 05 Jul 2020, Published online: 31 Jul 2020

References

  • Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014;384(9959):2027–2035.
  • Pinsky PF, Prorok PC, Yu K, et al. Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. Cancer. 2017;123(4):592–599.
  • Arnsrud Godtman R, Holmberg E, Lilja H, et al. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial. Eur Urol. 2015;68(3):354–360.
  • Farwell WR, Linder JA, Jha AK. Trends in prostate-specific antigen testing from 1995 through 2004. Arch Intern Med. 2007;167(22):2497–2502.
  • Melia J, Moss S, Johns L. Rates of prostate-specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: a cross-sectional study. BJU Int. 2004;94(1):51–56.
  • Smith DP, Supramaniam R, Marshall VR, et al. Prostate cancer and prostate-specific antigen testing in New South Wales. Med J Aust. 2008;189(6):315–318.
  • Drummond FJ, Carsin AE, Sharp L, et al. Trends in prostate specific antigen testing in Ireland: lessons from a country without guidelines. Ir J Med Sci. 2010;179(1):43–49.
  • Nordstrom T, Aly M, Clements MS, et al. Prostate-specific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, Despite no recommendations for PSA screening: results from a population-based study, 2003–2011. Eur Urol. 2013;63(3):419–425.
  • Regionala cancercentrum i samverkan. Rekommendationer om organiserad prostatacancertestning [accessed 2019 Oct 2]. Available from https://www.cancercentrum.se/samverkan/vara-uppdrag/prevention-och-tidig-upptackt/prostatacancertestning/2018.
  • Epstein JI, Egevad L, Amin MB, et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason grading of prostatic carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol. 2016;40(2):244–252.
  • Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
  • Russo A, Autelitano M, Bellini A, et al. Estimate of population coverage with the prostate specific antigen (PSA) test to screen for prostate cancer in a metropolitan area of northern Italy. J Med Screen. 2002;9(4):179–180.
  • Jonsson H, Holmström B, Duffy SW, et al. Uptake of prostate-specific antigen testing for early prostate cancer detection in Sweden. Int J Cancer. 2011;129(8):1881–1888.
  • Fenton JJ, Weyrich MS, Durbin S, et al. Prostate-specific antigen-based screening for prostate cancer: evidence report and systematic review for the US preventive services task force. JAMA. 2018;319(18):1914–1931.
  • Hanske J, Meyer CP, Sammon JD, et al. The influence of marital status on the use of breast, cervical, and colorectal cancer screening. Prev Med. 2016;89:140–145.
  • El-Haddad B, Dong F, Kallail KJ, et al. Association of marital status and colorectal cancer screening participation in the USA. Colorectal Dis. 2015;17(5):O108–O114.
  • Tomic K, Ventimiglia E, Robinson D, et al. Socioeconomic status and diagnosis, treatment, and mortality in men with prostate cancer. Nationwide population-based study. Int J Cancer. 2018;142(12):2478–2484.
  • Cavalli-Bjorkman N, Lambe M, Eaker S, et al. Differences according to educational level in the management and survival of colorectal cancer in Sweden. Eur J Cancer. 2011;47(9):1398–1406.
  • Eaker S, Halmin M, Bellocco R, et al. Social differences in breast cancer survival in relation to patient management within a National Health Care System (Sweden). Int J Cancer. 2009;124(1):180–187.
  • Berglund A, Garmo H, Robinson D, et al. Differences according to socioeconomic status in the management and mortality in men with high risk prostate cancer. Eur J Cancer. 2012;48(1):75–84.
  • Steenland K, Rodriguez C, Mondul A, et al. Prostate cancer incidence and survival in relation to education (United States). Cancer Causes Control. 2004;15(9):939–945.